INFORMAZIONI SU QUESTO EPISODIO
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: William Grady, MD
Guest: William Grady, MD
While colorectal cancer is the second most common cause of cancer deaths, only a third of people between the ages of 45 and 75 are compliant with screening recommendations. However, cell-free DNA blood-based tests could become a new option for colorectal cancer screening. Dr. Peter Buch sits down with GI expert Dr. William Grady to discuss the efficacy of this new test and where it is in the FDA approval process.
Inglese
Stati Uniti
IN QUESTO EPISODIO
TRASCRIZIONE 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
CERCA TRA GLI EPISODI PASSATI
Cerca gli episodi passati di GI Insights.
ALTRI EPISODI IN QUESTO PODCAST
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Vivek Kaul, MD
The American Society for Gastrointestinal Endoscopy (ASGE) recently released a new guideline on when to use endoscopic submucosal dissection (ESD) and endoscopic mucosal resection (EMR) in managing early esophageal and gast…
Host: Neilanjan Nandi, MD
Guest: Folasade P. May, MD, PhD, MPhil
Racial and ethnic bias prevent patients with colorectal cancer from receiving the highest quality of care. Dr. Neil Nandi is joined by Dr. Fola May, Assistant Professor of Medicine at UCLA, to discuss racial inequalitie…
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Aasma Shaukat, MD, MPH
While fecal immunochemical testing and multitarget stool DNA testing are commonly used to screen for colon cancer, screening rates remain low throughout the United States. With the introduction of blood-based testin…
Host: Neilanjan Nandi, MD
Guest: Samir Shah, MD
From new guideline recommendations to a concert featuring the American College of Gastroenterology’s official band, a lot is being done to help raise awareness of the importance of screening for colorectal cancer. So how can you help in…
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Aasma Shaukat, MD, MPH
Screening for colorectal cancer is unique because there are several screening options available. So how can we balance the latest ACG Clinical Guidelines with patient preferences, cultural context, and insurance cov…
Dichiarazione di non responsabilità: Il podcast e la grafica incorporati in questa pagina provengono da ReachMD, che è di proprietà del suo proprietario e non è affiliato o approvato da Listen Notes, Inc.
MODIFICA
Grazie, ci hai aiutato a mantenere aggiornato il database dei podcast.
